Most Common Side Effects of Polivy
Polivy (polatuzumab vedotin-piiq), used with bendamustine and rituximab to treat relapsed or refractory diffuse large B-cell lymphoma, has these frequent side effects from clinical trials: neutropenia (41%), thrombocytopenia (39%), anemia (31%), peripheral neuropathy (39%), fatigue (36%), diarrhea (31%), pyrexia (27%), decreased appetite (24%), and pneumonia (17%).[1][2]
How Often Do Serious Side Effects Happen?
Serious adverse reactions occur in 48% of patients. These include pneumonia (12%), infusion-related reactions (7%), and fatal events like sepsis or pneumonitis (4%). Neutropenia leads to febrile neutropenia in 16% of cases.[1][2]
Why Peripheral Neuropathy with Polivy?
Polivy is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells, but it often causes peripheral neuropathy due to microtubule disruption in nerves. Symptoms like numbness, tingling, or pain affect 40-50% of patients, worsening over cycles; 4% discontinue treatment because of it.[1][3]
Side Effects Compared to Bendamustine-Rituximab Alone
In the GO29365 trial, adding Polivy increased rates of neutropenia (41% vs 13%), thrombocytopenia (39% vs 21%), and peripheral neuropathy (39% vs 2%), but improved response rates (40% vs 18%). Pneumonia risk rose but was similar overall.[1][2]
What Do Patients Report Most?
Real-world data and patient forums highlight fatigue, neuropathy, nausea, and infections as top complaints. Neuropathy can persist post-treatment, and infections stem from low white blood cells; prophylactic antibiotics are often recommended.[2][4]
Managing Side Effects on Polivy
Dose delays or reductions handle 50% of cytopenias and neuropathy. Monitor blood counts weekly, use growth factors for neutropenia, and report neuropathy early. Infusion reactions (13%) are managed with premedication like acetaminophen and antihistamines.[1][3]
[1]: Polivy Prescribing Information (Genentech, 2023)
[2]: FDA Label for Polivy
[3]: GO29365 Trial (NEJM, 2019)
[4]: Drugs.com Polivy Side Effects